SKYTROFA:
The Freedom of Once Weekly
The #1 prescribed once-weekly treatment for pediatric GHD since 2021†
MORE THAN
10,000
patients have been prescribed SKYTROFA1*
In pediatric GHD treatment, SKYTROFA is the only GH that offers your patients all of these features:
Predictable release of unmodified somatropin over the course of one week with TransCon® technology2‑5‡
Auto-Injector designed to deliver the full dose and minimize the potential for wasted medication2
Room temperature storage for up to 6 months2,4,5§
A preservative-free formulation2,4,5
SKYTROFA demonstrated higher mean annualized height velocity (AHV) compared with a daily somatropin at week 52 in a clinical trial2,3
A treatment difference of 0.9 cm/year (95% CI: 0.2 to 1.5) at 52 weeks compared with daily somatropin (11.2 cm/year with SKYTROFA compared with 10.3 cm/year with daily somatropin)2,3II
heiGHt was a randomized, open-label, active-controlled, phase 3 study that compared the efficacy, safety, and tolerability of once-weekly SKYTROFA versus daily somatropin in children with GHD1,2* Click here to see full study design details.
Broad Coverage
Your local team is available to provide details on our expanded coverage across payors
Statement of Medical Necessity
Get your patients with pediatric GHD started on SKYTROFA today
Patient Support Program
Get to know the dedicated support team